HLA and TCR Recognition of Medications in Severe Cutaneous Adverse Reactions

ISSN: 1875-631X (Online)
ISSN: 1573-3955 (Print)


Volume 10, 2 Issues, 2014


Download PDF Flyer




Current Immunology Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Cecil Czerkinsky
Institut de Pharmacologie Moleculaire et Cellulaire
UMR 7275 CNRS-INSERM-UNISA
660 Route des Lucioles
Valbonne, 06560
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


HLA and TCR Recognition of Medications in Severe Cutaneous Adverse Reactions

Author(s): Ren-You Pan, Yi-Chih Wu, Wen-Hung Chung and Shuen-Iu Hung

Affiliation: Shuen-Iu Hung, Institute of Pharmacology, National Yang-Ming University, 155, Linong Street, Section 2, Beitou, Taipei 11221, Taiwan.

Abstract

Severe cutaneous adverse reactions (SCAR) include drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Although rare, SCAR has significant public health impact because of the unpredictability, high mortality and morbidity. The common culprit drugs for SCAR include aromatic antiepileptics (e.g., carbamazepine, phenytoin, lamotrigine, phenobarbital), antibiotics (e.g., sulfamethoxazole, sulfonamides, abacavir, nevirapine, dapsone), NSAIDs, and allopurinol, etc. Increasing studies revealed the strong genetic association between HLA alleles and SCAR. To explain how the interactions of a small chemical compound (drug/metabolite), HLA, TCR, and peptides induce the destructive T cell response in SCAR, three theories are proposed: the “hapten/prohapten” theory, the “pharmacological interaction with immune receptors” (p-i) concept, and the “altered peptide repertoire” model. In this article, we summarize important studies on the immunogenetic association between HLA and SCAR, review the molecular interaction of HLA/TCR/drug/peptide antigens, and discuss the potential pathological mechanistic models of HLA and TCR recognition of medications in SCAR. The accumulated knowledge will help to develop safer drugs, and thus facilitate preclinical immunotoxicity screening. Upon gaining insights into the molecular interaction in the immune synapse composing of the HLA/drug/peptide/TCR, we will advance our understandings to the pathogenesis of the SCAR, and a better strategy may be offered to avoid the occurrence, or improve the treatment of SCAR.




Keywords: Drug reaction with eosinophilia and systemic symptoms, human leukocyte antigens, severe cutaneous adverse reactions, Stevens-Johnson syndrome, T cell receptors, toxic epidermal necrolysis.

Download Free Rights and Permissions

  
  



Article Details

Volume: 10
Issue Number: 1
First Page: 51
Last Page: 61
Page Count: 11
DOI: 10.2174/1573395510666140717182714
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science